$MRNA just beat quarterly revenue estimates, and that got bulls re-energized today. The topline print came in stronger than expected thanks to continued demand for their mRNA portfolio, and the market is giving props for execution. Even though COVID-shot volumes aren’t what they used to be, Moderna’s pipeline and pricing power are keeping the revenue engine humming. This kind of beat matters for biotech and growth plays because it shows a company can still deliver in a tough environment where forward guidance is hard and competition is fierce. The stock’s feeling the love right now, but keep an eye on upcoming catalysts,  pipeline updates and trial data could swing sentiment again. So whether you’re trading the rip or stacking shares for the long haul, this one’s a reminder that solid execution still gets rewarded, even in a down biotech tape.